| http://www.w3.org/ns/prov#value | - Indeed, in this review, there was a strong relationship between the overall rate of response and ultimate success in phase III, suggesting that objective response, particularly for agents targeted critical mutated proteins or ???oncogenic drivers??? remains an important screening measure of clinical activity Two other areas of debate in phase II have been identified: i) Whether and how to enrich p
|
